Header

UZH-Logo

Maintenance Infos

Agomelatine for depression in schizophrenia: A case-series


Mutschler, Jochen; Rüsch, Nicolas; Schönfelder, Herdis; Herwig, Uwe; Brühl, Annette Beatrix; Grosshans, Martin; Rössler, Wulf; Russmann, Heike (2012). Agomelatine for depression in schizophrenia: A case-series. Psychopharmacology Bulletin, 45(1):35-43.

Abstract

OBJECTIVES: Agomelatine, a melatonin (MT1/MT2) receptor agonist and 5-HT2C receptor antagonist, is a new antidepressant and a potential therapeutic option for major depressive episodes and negative symptoms in persons with schizophrenia. We investigated such treatment outcomes with respect to antidepressant efficacy, safety, and tolerability.
METHODS: We report a consecutive case series of seven patients with schizophrenia and comorbid major depressive symptoms who received agomelatine for a period of at least six weeks in addition to stable doses of antipsychotic agents. General psychopathology, positive, negative and depressive symptoms were assessed with standardized interviews. Relevant blood parameters were assessed.
RESULTS: Depressive symptoms improved significantly. Positive symptoms remained stable, while negative symptoms and global psychopathology improved significantly. Agomelatine was well tolerated in most patients.
CONCLUSIONS: Our findings provide initial evidence that agomelatine is safe and efficacious in treating depressive symptoms in patients with schizophrenia. Furthermore, agomelatine seems to be effective for the treatment of negative symptoms. Randomized controlled trials are necessary to confirm these first observations.

Abstract

OBJECTIVES: Agomelatine, a melatonin (MT1/MT2) receptor agonist and 5-HT2C receptor antagonist, is a new antidepressant and a potential therapeutic option for major depressive episodes and negative symptoms in persons with schizophrenia. We investigated such treatment outcomes with respect to antidepressant efficacy, safety, and tolerability.
METHODS: We report a consecutive case series of seven patients with schizophrenia and comorbid major depressive symptoms who received agomelatine for a period of at least six weeks in addition to stable doses of antipsychotic agents. General psychopathology, positive, negative and depressive symptoms were assessed with standardized interviews. Relevant blood parameters were assessed.
RESULTS: Depressive symptoms improved significantly. Positive symptoms remained stable, while negative symptoms and global psychopathology improved significantly. Agomelatine was well tolerated in most patients.
CONCLUSIONS: Our findings provide initial evidence that agomelatine is safe and efficacious in treating depressive symptoms in patients with schizophrenia. Furthermore, agomelatine seems to be effective for the treatment of negative symptoms. Randomized controlled trials are necessary to confirm these first observations.

Statistics

Citations

Dimensions.ai Metrics
1 citation in Web of Science®
1 citation in Scopus®
1 citation in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

4 downloads since deposited on 13 Feb 2013
4 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Clinical and Social Psychiatry Zurich West (former)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2012
Deposited On:13 Feb 2013 13:55
Last Modified:24 Sep 2019 19:07
Publisher:MedWorks Media Global
ISSN:0048-5764
OA Status:Green
Free access at:Publisher DOI. An embargo period may apply.
Related URLs:http://www.medworksmedia.com/
PubMed ID:27738367

Download

Download PDF  'Agomelatine for depression in schizophrenia: A case-series'.
Preview
Content: Published Version
Filetype: PDF
Size: 274kB